CAS No. : 7280-37-7
(Synonyms: Piperazine estrone sulfate; Estrone sulfate piperazine salt)
| Size | Price | Stock |
|---|---|---|
| 5mg | $32 | In-stock |
| 10mg | $50 | In-stock |
| 50mg | $100 | In-stock |
| 100mg | $150 | In-stock |
| 500mg | $450 | In-stock |
| 1 g | Get quote | |
| 5 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-B1361 |
| M.Wt: | 436.56 |
| Formula: | C22H32N2O5S |
| Purity: | >98 % |
| Solubility: | DMSO : 110 mg/mL (ultrasonic) |
Estropipate (Piperazine estrone sulfate; Estrone sulfate piperazine salt) is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estropipate is an orally active estrogen receptor α agonist and a selective OATP1B1 inhibitor. Estropipate inhibits OATP1B1-mediated uptake of statin substrates. Estropipate regulates the estrogen signaling pathway and ameliorates sensory processing and arousal-related behavioral deficits in scn1lab-mutant zebrafish. Estropipate can be used in studies related to autism[1][2].
In Vitro: Estropipate (EPP) potently and selectively inhibits OATP1B1-mediated transport of Rosuvastatin (HY-17504A) in humans and cynomolgus monkeys, with IC50 values of 0.05 μM and 0.12 μM, respectively, while only exerting weak inhibitory effects on other hepatic uptake transporters[2].
Estropipate (1-100 μM; 0.25-5 minutes) selectively inhibits OATP1B1-mediated uptake of statins into human and cynomolgus monkey hepatocytes at a concentration of 1 μM, an effect that accounts for 44%-64% of the total hepatic uptake clearance of Rosuvastatin, Pitavastatin (HY-B0144A), and dehydrated Pravastatin; in contrast, Estropipate at 100 μM inhibits uptake mediated by all of OATP1B1, OATP1B3, OATP2B1, and NTCP[2].
In Vivo: Estropipate (EST) (10 μM; continuous water exposure; 5 to 7 days post-fertilization) acts as a potent inhibitor of autism spectrum disorder (ASD)-related behavioral phenotypes in scn1lab mutants, and reverses 12 out of 18 abnormal baseline parameters, including daytime resting episode frequency[1].
Estropipate (EPP) (0.3-6 mg/kg; p.o.; single administration; 1 hour prior to Rosuvastatin administration) dose-dependently increases the systemic exposure of Rosuvastatin in cynomolgus monkeys, and its mechanism of action is the selective inhibition of OATP1B1-mediated hepatic uptake[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.